SC
OLMA icon

Syon Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Syon Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,151
Closed -$76.7K – 642
2024
Q4 		$76.7K Buy
+13,151
New +$131K 0.01% 556

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

Syon Capital's OLMA Position: Q1 2025 in Review

Syon Capital sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 13,151 shares — an estimated $76.7K sold.

Syon Capital first reported a position in OLMA in Q4 2024 and held it in 1 quarter. The position peaked at $76.7K in Q4 2024. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

  • Syon Capital reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Syon Capital sold 13,151 Olema Pharmaceuticals shares in Q1 2025, an estimated $76.7K.
  • Syon Capital first reported a position in Olema Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Syon Capital's Olema Pharmaceuticals position peaked at $76.7K in Q4 2024.
  • 133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.